Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke
Authors:
- 1 August 2012
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (25) , 3677-3684
Abstract
Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective treatment for acute ischemic stroke, but can cause vascular damage leading to edema formation and hemorrhagic transformation (HT). In this review, we discuss how tPA contributes to the pathogenesis of vascular damage and highlight evidence to support combination therapy of tPA with pharmacological agents that are vascular protective. There is an unmet need to develop therapeutic interventions which target the underlying mechanisms of vascular damage after acute ischemic stroke in order to prevent HT and improve the safety and impact of tPA.Keywords
This publication has 87 references indexed in Scilit:
- 17β-estradiol attenuates breakdown of blood–brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemiaNeurobiology of Disease, 2011
- Minocycline Development for Acute Ischemic StrokeTranslational Stroke Research, 2011
- Thrombolysis With PlasminStroke, 2010
- Pre–Tissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral HemorrhageStroke, 2009
- Extension of the Thrombolytic Time Window With Minocycline in Experimental StrokeStroke, 2008
- Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemiaNeurosurgical Focus, 2007
- Cerebral Mast Cells Regulate Early Ischemic Brain Swelling and Neutrophil AccumulationJournal of Cerebral Blood Flow & Metabolism, 2006
- Gelatinase B and TIMP‐1 are regulated in a cell‐ and time‐dependent manner in association with neuronal death and glial reactivity after global forebrain ischemiaEuropean Journal of Neuroscience, 2002
- Hypertension and Its Treatment in the NINDS rt-PA Stroke TrialStroke, 1998
- Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic StrokeStroke, 1997